New kidney care centre set to be approved in Heywood
Date published: 30 August 2018
A Renal Dialysis Unit in Heywood looks set to be approved by the Planning and Licensing Committee on Monday (3 September).
Located at the site of a former mill on Schofield Street, the centre, a satellite of Salford Royal Hospital, would provide renal dialysis, renal outpatient care and general nephrology services, replacing existing services at Rochdale Infirmary.
The current facility could not be refurbished to meet the terms of the guidance and over 600 appointments annually would be transferred to the Heywood kidney care centre from the Salford clinic.
The former mill site has been unsuccessfully marketed for employment purposes for a period of at least six years, since being vacated by the previous occupiers, and the wider area of land associated with the mill building has been unused for circa 22 years, planners say.
Under the plans, the mill would be demolished, and a new centre built, providing 24 treatment stations, four consulting rooms and other ancillary facilities.
Planning officers have recommended granting the application subject to 16 recommended conditions, including starting the work no later than three years after being approved.
The application will be heard at the Planning and Licensing Committee at Number One Riverside on Monday at 6.15pm.
Do you have a story for us?
Let us know by emailing news@rochdaleonline.co.uk
All contact will be treated in confidence.
Most Viewed News Stories
- 1Local Multi Academy Trust welcomes new school
- 2Rochdale Gramophone Society to close after 93 years
- 3Council announces plans for Hopwood Hall Estate, - as angry Hopwood DePree holds "urgent" public...
- 4Friday and Saturday’s fire festival cancelled due to severe weather
- 5MP spotlights ‘hidden horror’ of domestic abuse with dedicated surgery
To contact the Rochdale Online news desk, email news@rochdaleonline.co.uk or visit our news submission page.
To get the latest news on your desktop or mobile, follow Rochdale Online on Twitter and Facebook.